ERBB2 and gastric cancer: The European Society of Medical Oncology (ESMO) recommends HER2 testing for metastatic GC, while the American Society of Clinical Oncology (ASCO) recommends HER2 testing on either primary or metastatic lesions for all patients with a diagnosed GC who are able to tolerate combination therapy [92,93].